NKGen Biotech (NKGN) shares saw a substantial increase on Monday, with a surge in trading volume. However, no recent news appears to explain the +20% rise in stock price. The company will be presenting at an upcoming Alzheimer’s & Parkinson’s Drug Development Summit, where it will discuss its NK cell therapy for neurodegenerative diseases and share preclinical and clinical data. Despite the lack of apparent news driving the share surge, NKGen Biotech recently closed a $5 million loan and has stated its focus on Phase 2 clinical trials for Alzheimer’s and Parkinson’s while prioritizing resource efficiency.